<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1778">
  <stage>Registered</stage>
  <submitdate>12/12/2007</submitdate>
  <approvaldate>12/12/2007</approvaldate>
  <nctid>NCT00574041</nctid>
  <trial_identification>
    <studytitle>How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose</studytitle>
    <scientifictitle>An Open-Label Study to Examine the Difference in Tolerability Associated With Titration Of Dose on Initiation of Avonex therapY (TODAY)</scientifictitle>
    <utrn />
    <trialacronym>TODAY</trialacronym>
    <secondaryid>AUS-8002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsing Remitting Multiple Sclerosis</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Interferon beta-1a

Experimental: 1 - titrated dose of Avonex

Active Comparator: 2 - full dose Avonex


Treatment: drugs: Interferon beta-1a
injected, once a week

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the mean severity of episodes of FLS during the 4 week titration phase</outcome>
      <timepoint>4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the mean severity and duration of FLS episodes in post-titration phase</outcome>
      <timepoint>throughout study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of clinically-definite relapsing-remitting multiple sclerosis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any Product Information-specified contraindications to interferon-beta therapy, or
             other medical factors which, in the opinion of the investigator, make the subject
             unsuitable for interferon-beta therapy

          -  Use of AVONEX, but not other interferon therapies, in the 3 months prior to
             randomisation into the study

          -  A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia,
             septicemia) within 30 days prior to randomisation.

          -  History of seizure in the 3 months prior to randomisation

          -  History of suicidal ideation or severe depression within the 3 months prior to
             randomisation.

          -  Other inclusion and exclusion criteria may apply per study protocol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>19</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Coordinating Research Site - Malvern</hospital>
    <postcode>3144 - Malvern</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biogen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to find out if starting at low dose Avonex and slowly increasing to full dose
      will improve flu like symptoms as a side effect of Avonex treatment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00574041</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Biogen-Idec Investigator</name>
      <address>Biogen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>